psmad2 3 antibody Search Results


human phospho-smad2/3 (s465/s467) antibody  (Bio-Techne corporation)
93
Bio-Techne corporation human phospho-smad2/3 (s465/s467) antibody
Human Phospho Smad2/3 (S465/S467) Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human phospho-smad2/3 (s465/s467) antibody/product/Bio-Techne corporation
Average 93 stars, based on 1 article reviews
human phospho-smad2/3 (s465/s467) antibody - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
rabbit psmad2/3  (LuBioScience GmbH)
90
LuBioScience GmbH rabbit psmad2/3
Rabbit Psmad2/3, supplied by LuBioScience GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit psmad2/3/product/LuBioScience GmbH
Average 90 stars, based on 1 article reviews
rabbit psmad2/3 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-psmad2  (Absolute Biotech Inc)
90
Absolute Biotech Inc anti-psmad2
Time dependent changes of transforming growth factor (TGF)-β1 (A–C, in order, Day 1, 7 and 21) and phospho-Smad2 <t>(pSmad2)</t> (D–F, in order, Day 1, 7 and 21) expression in bleomycin-induced pulmonary fibrosis. Representative positive cells are indicated by red arrows or blue arrows, respectively. Scale bar, 50 µ m. Bar graph of TGF-β1 (G) and pSmad2 (H) positive area. Data are means ± SEM (n=3–5).
Anti Psmad2, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-psmad2/product/Absolute Biotech Inc
Average 90 stars, based on 1 article reviews
anti-psmad2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
p-smad2/3 (cat# af5920)  (Beyotime)
90
Beyotime p-smad2/3 (cat# af5920)
VX-509 downregulates Nodal and its <t>downstream</t> <t>protein</t> <t>p-Smad2/3</t> in colorectal cancer-derived cancer stem cells. A: Volcano plot of differentially expressed genes in the HT29 cancer stem cells (CSCs) Mock and VX-509-treated groups; B: Gene Ontology enrichment image of the differentially expressed genes; C: Nodal mRNA expression levels in the colorectal cancer (CRC)-derived CSCs Mock and VX-509-treated group; D-F: Protein expression levels of Nodal, p-Smad2/3 (D) and JAK3 (F) in CRC-derived CSCs treated with different concentrations of VX-509 (E). Densitometric analysis of Nodal and p-Smad2/3, normalized against GAPDH. n = 3. a P < 0.05, b P < 0.01, c P < 0.001, d P < 0.0001 compared to the HCT116 cancer stem cells Mock group and HT29 cancer stem cells Mock group. CSC: Cancer stem cell; DEG: Differentially expressed gene.
P Smad2/3 (Cat# Af5920), supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-smad2/3 (cat# af5920)/product/Beyotime
Average 90 stars, based on 1 article reviews
p-smad2/3 (cat# af5920) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Time dependent changes of transforming growth factor (TGF)-β1 (A–C, in order, Day 1, 7 and 21) and phospho-Smad2 (pSmad2) (D–F, in order, Day 1, 7 and 21) expression in bleomycin-induced pulmonary fibrosis. Representative positive cells are indicated by red arrows or blue arrows, respectively. Scale bar, 50 µ m. Bar graph of TGF-β1 (G) and pSmad2 (H) positive area. Data are means ± SEM (n=3–5).

Journal: Experimental Animals

Article Title: Time course of histopathology of bleomycin-induced pulmonary fibrosis using an intratracheal sprayer in mice

doi: 10.1538/expanim.23-0048

Figure Lengend Snippet: Time dependent changes of transforming growth factor (TGF)-β1 (A–C, in order, Day 1, 7 and 21) and phospho-Smad2 (pSmad2) (D–F, in order, Day 1, 7 and 21) expression in bleomycin-induced pulmonary fibrosis. Representative positive cells are indicated by red arrows or blue arrows, respectively. Scale bar, 50 µ m. Bar graph of TGF-β1 (G) and pSmad2 (H) positive area. Data are means ± SEM (n=3–5).

Article Snippet: Tissue sections were overlaid with the 1:100 dilution of anti-TGF-β1 (LifeSpan BioSciences, Inc., Seattle, WA, USA) or anti- pSmad2 (LifeSpan BioSciences, Inc.) and then incubated for overnight at 4°C.

Techniques: Expressing

VX-509 downregulates Nodal and its downstream protein p-Smad2/3 in colorectal cancer-derived cancer stem cells. A: Volcano plot of differentially expressed genes in the HT29 cancer stem cells (CSCs) Mock and VX-509-treated groups; B: Gene Ontology enrichment image of the differentially expressed genes; C: Nodal mRNA expression levels in the colorectal cancer (CRC)-derived CSCs Mock and VX-509-treated group; D-F: Protein expression levels of Nodal, p-Smad2/3 (D) and JAK3 (F) in CRC-derived CSCs treated with different concentrations of VX-509 (E). Densitometric analysis of Nodal and p-Smad2/3, normalized against GAPDH. n = 3. a P < 0.05, b P < 0.01, c P < 0.001, d P < 0.0001 compared to the HCT116 cancer stem cells Mock group and HT29 cancer stem cells Mock group. CSC: Cancer stem cell; DEG: Differentially expressed gene.

Journal: World Journal of Stem Cells

Article Title: VX-509 attenuates the stemness characteristics of colorectal cancer stem-like cells by regulating the epithelial-mesenchymal transition through Nodal/Smad2/3 signaling

doi: 10.4252/wjsc.v16.i2.207

Figure Lengend Snippet: VX-509 downregulates Nodal and its downstream protein p-Smad2/3 in colorectal cancer-derived cancer stem cells. A: Volcano plot of differentially expressed genes in the HT29 cancer stem cells (CSCs) Mock and VX-509-treated groups; B: Gene Ontology enrichment image of the differentially expressed genes; C: Nodal mRNA expression levels in the colorectal cancer (CRC)-derived CSCs Mock and VX-509-treated group; D-F: Protein expression levels of Nodal, p-Smad2/3 (D) and JAK3 (F) in CRC-derived CSCs treated with different concentrations of VX-509 (E). Densitometric analysis of Nodal and p-Smad2/3, normalized against GAPDH. n = 3. a P < 0.05, b P < 0.01, c P < 0.001, d P < 0.0001 compared to the HCT116 cancer stem cells Mock group and HT29 cancer stem cells Mock group. CSC: Cancer stem cell; DEG: Differentially expressed gene.

Article Snippet: For antibodies, Oct-4 (Cat# 381335, ZEN-BIOSCIENCE, Chengdu, China), Nanog (Cat# 381167) and SOX2 (Cat# 864316) were purchased from ZEN-BIOSCIENCE; CD133 (Cat# ab216323), CD44 (Cat# ab189524) and Nodal (Cat# ab55676) were purchased from Abcam; β-actin (Cat# 20536-1-AP) and GAPDH (Cat# 10494-1-AP) were purchased from Proteintech; E-cadherin (Cat# AF6759), N-cadherin (Cat# AF5237), vimentin (Cat# AF1975), JAK3 (Cat# AF7314), p-Smad2/3 (Cat# AF5920), goat anti-rabbit immunoglobulin (Ig)G antibody (Cat# A0208) and goat anti-mouse IgG antibody (Cat# A0216) were purchased from Beyotime.

Techniques: Derivative Assay, Expressing

VX-509 reverses the increase in epithelial-mesenchymal transition progression induced by Nodal over expression in colorectal cancer-derived cancer stem cells. A: Morphological changes in Nodal-stimulated colorectal cancer (CRC)-derived cancer stem cells (CSCs) treated with different concentrations of VX-509 observed via microscopy; B and C: The effects of VX-509 on the protein expression levels of E-cadherin, N-cadherin, and vimentin in Nodal-stimulated CRC-derived CSCs were detected by western blot and relative statistical analysis, normalized against GAPDH; D and E: The effects of VX-509 on the protein expression levels of Nodal and p-Smad2/3 in Nodal-stimulated CRC-derived CSCs were detected by western blot and relative statistical analysis, normalized against GAPDH. n = 3. a P < 0.05, c P < 0.001, e P < 0.05 compared to the HCT116 cancer stem cells Mock group and HT29 cancer stem cells Mock group. f P < 0.05, g P < 0.01, h P < 0.0001 compared to the HCT116 cancer stem cells Nodal group and HT29 CSCs Nodal group.

Journal: World Journal of Stem Cells

Article Title: VX-509 attenuates the stemness characteristics of colorectal cancer stem-like cells by regulating the epithelial-mesenchymal transition through Nodal/Smad2/3 signaling

doi: 10.4252/wjsc.v16.i2.207

Figure Lengend Snippet: VX-509 reverses the increase in epithelial-mesenchymal transition progression induced by Nodal over expression in colorectal cancer-derived cancer stem cells. A: Morphological changes in Nodal-stimulated colorectal cancer (CRC)-derived cancer stem cells (CSCs) treated with different concentrations of VX-509 observed via microscopy; B and C: The effects of VX-509 on the protein expression levels of E-cadherin, N-cadherin, and vimentin in Nodal-stimulated CRC-derived CSCs were detected by western blot and relative statistical analysis, normalized against GAPDH; D and E: The effects of VX-509 on the protein expression levels of Nodal and p-Smad2/3 in Nodal-stimulated CRC-derived CSCs were detected by western blot and relative statistical analysis, normalized against GAPDH. n = 3. a P < 0.05, c P < 0.001, e P < 0.05 compared to the HCT116 cancer stem cells Mock group and HT29 cancer stem cells Mock group. f P < 0.05, g P < 0.01, h P < 0.0001 compared to the HCT116 cancer stem cells Nodal group and HT29 CSCs Nodal group.

Article Snippet: For antibodies, Oct-4 (Cat# 381335, ZEN-BIOSCIENCE, Chengdu, China), Nanog (Cat# 381167) and SOX2 (Cat# 864316) were purchased from ZEN-BIOSCIENCE; CD133 (Cat# ab216323), CD44 (Cat# ab189524) and Nodal (Cat# ab55676) were purchased from Abcam; β-actin (Cat# 20536-1-AP) and GAPDH (Cat# 10494-1-AP) were purchased from Proteintech; E-cadherin (Cat# AF6759), N-cadherin (Cat# AF5237), vimentin (Cat# AF1975), JAK3 (Cat# AF7314), p-Smad2/3 (Cat# AF5920), goat anti-rabbit immunoglobulin (Ig)G antibody (Cat# A0208) and goat anti-mouse IgG antibody (Cat# A0216) were purchased from Beyotime.

Techniques: Over Expression, Derivative Assay, Microscopy, Expressing, Western Blot